GlobeNewsWire
18 May 2026, 01:54 UTC · 17w ago
Verdict
Headline leans bearish. We score TRDA −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Entrada Therapeutics' Phase 1/2 ELEVATE-44-201 clinical trial showed only a slight increase in a critical muscle-protecting protein, well below the level needed for the drug to be competitive in the Duchenne market.
More negative than 99% of claims this week
Shares of Entrada Therapeutics fell by nearly 57.3% on May 7, 2026, following the release of the clinical trial results.
So whatA nearly 57% single-day crash represents a massive, instantaneous destruction of market capitalization and a severe repricing of the company's risk profile.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
Top 1 mover · tap to explore
More negative than 98% of claims this week
The Schall Law Firm is investigating Entrada Therapeutics for potential securities law violations related to the company's characterization of the underwhelming clinical results as 'positive.'
More negative than 86% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a fraud investigation and experienced a nearly 58% stock price drop following disappointing clinical study results.
More negative than 88% of ticker scores this week
The company is the subject of a fraud investigation by a shareholder rights litigation firm.
More negative than 88% of ticker scores this week
The company is the subject of a fraud investigation by a shareholder rights litigation firm.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
GlobeNewsWire
53m ago
+6.6%
Price is moving against the score
$6.80 vs $6.38 close before publication (May 15) · not market-adjusted
TRDA chart →
